Skip to content

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04756492
Enrollment
100
Registered
2021-02-16
Start date
2021-02-15
Completion date
2023-02-15
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital

Brief summary

Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function

Detailed description

This study will be prospectively analyzing the clinical data of LN patients who received standard immunosuppressive therapy and were regularly followed up at our center for more than six months. These patients will not change treatment regimen during the six months. As remission is an independent predictor of good long term prognosis in lupus nephritis. We aim to examine the predictors of sustained complete renal remission in patients with lupus nephritis at Sohag University Hospital and to analyze data of lupus nephritis patients to find parameters that can predict remission and improve outcome of our cases

Interventions

DRUGsandimmun

follow up for treatment response

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* o Patients diagnosed with LN at Sohag University Hospital * Patients in regular follow-up for more than six months after immunosuppressive therapy * Baseline urinary protein/creatinine ratio (UPCR) more than 1 g/g * Baseline C3 less than 55 mg/ dl * No change in immunosuppressive therapy within six months

Exclusion criteria

* o Patients with incomplete pathological data and the number of glomeruli being \<10 per biopsy specimen * Age \<14 years old End-stage renal disease (ESRD) status on admission (sustained estimated glomerular filtration rate (eGFR) \<15 ml/min per 1.73m2) * Patients with advanced comorbid conditions like advanced liver cirrhosis or heart failure or malignancy

Design outcomes

Primary

MeasureTime frameDescription
complete renal response6 monthsAlb \_35 g/l, UPCR\<0.3 g/g, a normal range of sCr or at a level increasing no more than 15% from baseline and without lupus flares.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026